Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Merck says Phase 3 KEYNOTE-522 trial met dual primary endpoint » 06:46
05/13/21
05/13
06:46
05/13/21
06:46
MRK

Merck

$77.99 /

+0.54 (+0.70%)

Merck announced positive…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$77.99 /

+0.54 (+0.70%)

MRK Merck
$77.99 /

+0.54 (+0.70%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
MRK Merck
$77.99 /

+0.54 (+0.70%)

MRK Merck
$77.99 /

+0.54 (+0.70%)

MRK Merck
$77.99 /

+0.54 (+0.70%)

MRK Merck
$77.99 /

+0.54 (+0.70%)

Monday
Options
Merck call volume above normal and directionally bullish » 13:45
05/10/21
05/10
13:45
05/10/21
13:45
MRK

Merck

$78.82 /

+0.395 (+0.50%)

Bullish option flow…

Bullish option flow detected in Merck with 20,248 calls trading, 1.5x expected, and implied vol increasing almost 2 points to 19.24%. Jun-21 80 calls and Jun-21 85 calls are the most active options, with total volume in those strikes near 5,700 contracts. The Put/Call Ratio is 0.17. Earnings are expected on July 29th.

ShowHide Related Items >><<
MRK Merck
$78.82 /

+0.395 (+0.50%)

MRK Merck
$78.82 /

+0.395 (+0.50%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
MRK Merck
$78.82 /

+0.395 (+0.50%)

MRK Merck
$78.82 /

+0.395 (+0.50%)

MRK Merck
$78.82 /

+0.395 (+0.50%)

MRK Merck
$78.82 /

+0.395 (+0.50%)

Hot Stocks
ALX Oncology announces first patient dosed in ASPEN-03 phase 2 study of ALX148 » 07:53
05/10/21
05/10
07:53
05/10/21
07:53
ALXO

ALX Oncology

$65.01 /

+2.07 (+3.29%)

, MRK

Merck

$78.42 /

+0.64 (+0.82%)

ALX Oncology (ALXO) in…

ALX Oncology (ALXO) in partnership with Merck (MRK) announced the first patient has been dosed in the Phase 2 ASPEN-03 study evaluating the combination of ALX148, a next generation CD47 blocker, with KEYTRUDA, Merck's anti-PD-1 therapy, for the treatment of patients with advanced head and neck squamous cell carcinoma. ASPEN-03 is an open-label, randomized phase 2 multi-center study of the anti-tumor efficacy of ALX148 plus pembrolizumab in patients with first line metastatic or unresectable, recurrent PD-L1 positive HNSCC. This study is being conducted in collaboration with Merck and is based upon promising clinical data reported from the ASPEN-01 Phase 1 study, which provided the basis for ALX148's Fast Track designation in HNSCC granted by the U.S. Food and Drug Administration.

ShowHide Related Items >><<
MRK Merck
$78.42 /

+0.64 (+0.82%)

ALXO ALX Oncology
$65.01 /

+2.07 (+3.29%)

ALXO ALX Oncology
$65.01 /

+2.07 (+3.29%)

05/04/21 Credit Suisse
ALX Oncology assumed with an Outperform at Credit Suisse
04/26/21 Credit Suisse
ALX Oncology assumed with an Outperform at Credit Suisse
04/06/21 UBS
ALX Oncology initiated with a Buy at UBS
03/05/21 Piper Sandler
ALX Oncology collab provides pipeline expansion opportunity, says Piper Sandler
MRK Merck
$78.42 /

+0.64 (+0.82%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
MRK Merck
$78.42 /

+0.64 (+0.82%)

ALXO ALX Oncology
$65.01 /

+2.07 (+3.29%)

  • 13
    Jan
  • 10
    Dec
  • 17
    Jul
MRK Merck
$78.42 /

+0.64 (+0.82%)

MRK Merck
$78.42 /

+0.64 (+0.82%)

MRK Merck
$78.42 /

+0.64 (+0.82%)

ALXO ALX Oncology
$65.01 /

+2.07 (+3.29%)

Friday
Hot Stocks
Merck declares May 17 as record date for Organon spinoff » 13:05
05/07/21
05/07
13:05
05/07/21
13:05
MRK

Merck

$77.96 /

+0.18 (+0.23%)

, OGN

Organon

/

+

Merck (MRK) announced…

Merck (MRK) announced that its board of directors approved the separation of Organon & Co. (OGN) and declared a special dividend distribution of one-tenth of a share of Organon common stock for every Merck common share outstanding as of the close of business on May 17, the record date for the distribution. The company also announced that the U.S. Securities and Exchange Commission has declared effective the Registration Statement on Form 10 filed by Organon. The Form 10 includes information regarding Organon's business and strategy as well as details on the spinoff, which is expected to be completed on June 2. Merck expects the special dividend of Organon stock will be distributed on June 2. The New York Stock Exchange has authorized the listing of Organon common stock under the symbol "OGN". Organon has been advised that trading in its common stock is expected to begin on a "when issued" basis on May 14, 2021, under the symbol "OGN.WI." "When issued" trading of Organon common stock will continue until Merck pays the special dividend distribution of Organon common stock on June 2, 2021. Organon "when issued" trades are expected to settle after June 2, 2021, with shares of Organon as a standalone company. Beginning on May 14, 2021, and continuing through June 2, 2021, Merck expects that common shares of Merck will trade in two markets on the NYSE: "regular-way" under the symbol "MRK" and in the "ex-distribution" market under the symbol "MRK.WI." Merck shares trading under "MRK" will carry the right to receive shares of Organon through the special dividend distribution. Merck shares trading under "MRK.WI" will not carry the right to receive shares of Organon through the special dividend distribution. Merck shareholders who sell their shares in the "regular-way" market on or before June 2, 2021, will also be selling their entitlement to receive the Organon special dividend distribution of Organon common stock. Merck shareholders are encouraged to consult with their financial advisors regarding the specific consequences of selling Merck common shares on or before June 2, 2021. On June 3, 2021, regular-way trading will commence on the NYSE for Organon under the symbol "OGN" and will continue for Merck under the symbol "MRK." "We are pleased to announce the full details of Organon's spinoff from Merck, commencing later this month. This spinoff will position Organon as a successful, independent, publicly traded company with a compelling portfolio of important medicines, particularly in women's health. Organon will have a significant impact on women's health around the world, providing benefits to patients and shareholders alike," said Rob Davis, president, Merck.

ShowHide Related Items >><<
MRK Merck
$77.96 /

+0.18 (+0.23%)

MRK Merck
$77.96 /

+0.18 (+0.23%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
OGN Organon
/

+

MRK Merck
$77.96 /

+0.18 (+0.23%)

MRK Merck
$77.96 /

+0.18 (+0.23%)

MRK Merck
$77.96 /

+0.18 (+0.23%)

MRK Merck
$77.96 /

+0.18 (+0.23%)

Over a week ago
Hot Stocks
Fusion Pharmaceuticals announces clinical trial collaboration with Merck » 08:23
05/06/21
05/06
08:23
05/06/21
08:23
FUSN

Fusion Pharmaceuticals

$8.99 /

+0.37 (+4.29%)

, MRK

Merck

$77.71 /

+1.71 (+2.25%)

Fusion Pharmaceuticals…

Fusion Pharmaceuticals (FUSN) announced that it has entered into a clinical trial collaboration with a subsidiary of Merck (MRK) to evaluate Fusion's lead candidate, (FPI-1434), in combination with Merck's anti-PD-1 therapy, KEYTRUDA, in patients with solid tumors expressing insulin-like growth factor 1 receptor. The planned Phase 1/2 combination trial will evaluate safety, tolerability and pharmacokinetics of FPI-1434 in combination with pembrolizumab and is expected to initiate approximately six to nine months after achieving the recommended Phase 2 dose in the ongoing Phase 1 study of FPI-1434 monotherapy. Under the terms of the agreement, Fusion will sponsor the study and Merck will supply KEYTRUDA.

ShowHide Related Items >><<
MRK Merck
$77.71 /

+1.71 (+2.25%)

FUSN Fusion Pharmaceuticals
$8.99 /

+0.37 (+4.29%)

FUSN Fusion Pharmaceuticals
$8.99 /

+0.37 (+4.29%)

07/21/20
Fly Intel: Top five analyst initiations
07/21/20 Morgan Stanley
Fusion Pharmaceuticals initiated with an Overweight at Morgan Stanley
07/21/20 Wedbush
Wedbush bullish on Fusion Pharmaceuticals, initiates with an Outperform
07/21/20 Jefferies
Fusion Pharmaceuticals initiated with a Buy at Jefferies
MRK Merck
$77.71 /

+1.71 (+2.25%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
MRK Merck
$77.71 /

+1.71 (+2.25%)

FUSN Fusion Pharmaceuticals
$8.99 /

+0.37 (+4.29%)

  • 26
    Jun
MRK Merck
$77.71 /

+1.71 (+2.25%)

MRK Merck
$77.71 /

+1.71 (+2.25%)

MRK Merck
$77.71 /

+1.71 (+2.25%)

FUSN Fusion Pharmaceuticals
$8.99 /

+0.37 (+4.29%)

Hot Stocks
Merck, Eisai receive FDA priority review for KEYTRUDA plus LENVIMA » 06:44
05/06/21
05/06
06:44
05/06/21
06:44
MRK

Merck

$77.71 /

+1.71 (+2.25%)

, ESALY

Eisai

$66.24 /

+0.89 (+1.36%)

Merck (MRK) and Eisai…

Merck (MRK) and Eisai (ESALY) announced that the U.S. FDA has accepted and granted priority review for applications seeking two new approvals for the combination of KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. The first set of applications are for the first-line treatment of patients with advanced renal cell carcinoma, based on progression-free survival, overall survival and objective response rate data from the pivotal Phase 3 CLEAR study. The second set of applications are for the treatment of patients with advanced endometrial carcinoma who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation, based on PFS, OS and ORR data from the pivotal Phase 3 KEYNOTE-775/Study 309 trial. These are the first applications to be submitted in the U.S. for this combination therapy based on Phase 3 clinical data. The FDA has set Prescription Drug User Fee Act dates, or target action dates, of August 25 and 26, 2021, for the advanced RCC sNDA and sBLA applications, respectively, and September 3, 2021, for the advanced endometrial carcinoma applications.

ShowHide Related Items >><<
MRK Merck
$77.71 /

+1.71 (+2.25%)

ESALY Eisai
$66.24 /

+0.89 (+1.36%)

MRK Merck
$77.71 /

+1.71 (+2.25%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
ESALY Eisai
$66.24 /

+0.89 (+1.36%)

01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
11/05/20 Jefferies
Eisai upgraded to Buy from Hold at Jefferies
09/08/20 Jefferies
Eisai downgraded to Hold from Buy at Jefferies
MRK Merck
$77.71 /

+1.71 (+2.25%)

MRK Merck
$77.71 /

+1.71 (+2.25%)

MRK Merck
$77.71 /

+1.71 (+2.25%)

ESALY Eisai
$66.24 /

+0.89 (+1.36%)

MRK Merck
$77.71 /

+1.71 (+2.25%)

Hot Stocks
FDA approves Merck's KEYTRUDA+Trastuzumab in GEJ adenocarcinoma » 16:46
05/05/21
05/05
16:46
05/05/21
16:46
MRK

Merck

$77.71 /

+1.71 (+2.25%)

The company states:…

The company states: "Merck announced that the FDA has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction, or GEJ, adenocarcinoma. This indication is approved under accelerated approval based on tumor response rate and durability of response; continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. This approval is based on data from the ongoing Phase 3 KEYNOTE-811 trial, in which KEYTRUDA in combination with trastuzumab and either 5-fluorouracil plus cisplatin or capecitabine plus oxaliplatin demonstrated a statistically significant objective response rate (ORR) of 74% for patients who received the regimen with KEYTRUDA versus 52% for those who received trastuzumab and chemotherapy alone (pless than0.0001). For patients who received the regimen with KEYTRUDA, the complete response rate was 11% and the partial response rate was 63%. For patients who received trastuzumab and chemotherapy alone, the complete response rate was 3.1% and the partial response rate was 49%."

ShowHide Related Items >><<
MRK Merck
$77.71 /

+1.71 (+2.25%)

MRK Merck
$77.71 /

+1.71 (+2.25%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
MRK Merck
$77.71 /

+1.71 (+2.25%)

MRK Merck
$77.71 /

+1.71 (+2.25%)

MRK Merck
$77.71 /

+1.71 (+2.25%)

MRK Merck
$77.71 /

+1.71 (+2.25%)

Options
Merck call volume above normal and directionally bullish » 14:25
05/05/21
05/05
14:25
05/05/21
14:25
MRK

Merck

$77.45 /

+1.45 (+1.91%)

Bullish option flow…

Bullish option flow detected in Merck with 20,225 calls trading, 1.4x expected, and implied vol increasing over 1 point to 21.31%. May-21 78.5 calls and May-21 77 calls are the most active options, with total volume in those strikes near 4,700 contracts. The Put/Call Ratio is 0.23. Earnings are expected on July 29th.

ShowHide Related Items >><<
MRK Merck
$77.45 /

+1.45 (+1.91%)

MRK Merck
$77.45 /

+1.45 (+1.91%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
MRK Merck
$77.45 /

+1.45 (+1.91%)

MRK Merck
$77.45 /

+1.45 (+1.91%)

MRK Merck
$77.45 /

+1.45 (+1.91%)

MRK Merck
$77.45 /

+1.45 (+1.91%)

Hot Stocks
FDA grants pembrolizumab accelerated approval for HER2-positive gastric cancer » 14:24
05/05/21
05/05
14:24
05/05/21
14:24
MRK

Merck

$77.45 /

+1.45 (+1.91%)

The Food and Drug…

The Food and Drug Administration announced that it has granted accelerated approval to pembrolizumab, or Keytruda, from Merck in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma. Reference Link

ShowHide Related Items >><<
MRK Merck
$77.45 /

+1.45 (+1.91%)

MRK Merck
$77.45 /

+1.45 (+1.91%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
MRK Merck
$77.45 /

+1.45 (+1.91%)

MRK Merck
$77.45 /

+1.45 (+1.91%)

MRK Merck
$77.45 /

+1.45 (+1.91%)

MRK Merck
$77.45 /

+1.45 (+1.91%)

Initiation
Mereo BioPharma initiated with a Buy at BTIG » 07:18
05/05/21
05/05
07:18
05/05/21
07:18
MREO

Mereo BioPharma

$3.52 /

+0.015 (+0.43%)

, MRK

Merck

$76.00 /

+0.03 (+0.04%)

, RHHBY

Roche

$40.73 /

-0.62 (-1.50%)

BTIG analyst Yun Zhong…

BTIG analyst Yun Zhong initiated coverage of Mereo BioPharma (MREO) with a Buy rating and $10 price target. The stock appears to be "significantly undervalued" given the "abundant" proof-of-concept data that is de-risking its "diversified" pipeline, the analyst tells investors in a research note. Roche (RHHBY) and Merck's (MRK) positive data provide strong validation for Mereo's anti-TIGIT monoclonal antibody given the structural similarity, Zhong adds.

ShowHide Related Items >><<
RHHBY Roche
$40.73 /

-0.62 (-1.50%)

MRK Merck
$76.00 /

+0.03 (+0.04%)

MREO Mereo BioPharma
$3.52 /

+0.015 (+0.43%)

MREO Mereo BioPharma
$3.52 /

+0.015 (+0.43%)

04/05/21 Needham
Mereo BioPharma initiated with a Buy at Needham
MRK Merck
$76.00 /

+0.03 (+0.04%)

04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
RHHBY Roche
$40.73 /

-0.62 (-1.50%)

03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
RHHBY Roche
$40.73 /

-0.62 (-1.50%)

MRK Merck
$76.00 /

+0.03 (+0.04%)

  • 10
    Feb
RHHBY Roche
$40.73 /

-0.62 (-1.50%)

MRK Merck
$76.00 /

+0.03 (+0.04%)

RHHBY Roche
$40.73 /

-0.62 (-1.50%)

MRK Merck
$76.00 /

+0.03 (+0.04%)

MREO Mereo BioPharma
$3.52 /

+0.015 (+0.43%)

MRK Merck
$76.00 /

+0.03 (+0.04%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.